Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa

W Gulliver; CC Zouboulis; Errol Prens; GBE Jemec; T Tzellos

doi:10.1007/s11154-016-9328-5

Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa

W Gulliver, CC Zouboulis, Errol Prens, GBE Jemec, T Tzellos

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

203 Citations (Scopus)

18 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	343-351
Number of pages	9
Journal	Reviews in Endocrine & Metabolic Disorders
Volume	17
Issue number	3
DOIs	https://doi.org/10.1007/s11154-016-9328-5
Publication status	Published - 2016

Research programs

EMC MM-03-61-05-A

Access to Document

10.1007/s11154-016-9328-5

REPUB_94952_OA.pdfFinal published version, 865 KB

http://hdl.handle.net/1765/94952

Cite this

@article{cbcf1bbdfb964414aefa0a6080419fb4,

title = "Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa",

author = "W Gulliver and CC Zouboulis and Errol Prens and GBE Jemec and T Tzellos",

year = "2016",

doi = "10.1007/s11154-016-9328-5",

language = "Undefined/Unknown",

volume = "17",

pages = "343--351",

journal = "Reviews in Endocrine & Metabolic Disorders",

issn = "1389-9155",

publisher = "Springer Netherlands",

number = "3",

}

TY - JOUR

T1 - Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa

AU - Gulliver, W

AU - Zouboulis, CC

AU - Prens, Errol

AU - Jemec, GBE

AU - Tzellos, T

PY - 2016

Y1 - 2016

U2 - 10.1007/s11154-016-9328-5

DO - 10.1007/s11154-016-9328-5

M3 - Article

C2 - 26831295

SN - 1389-9155

VL - 17

SP - 343

EP - 351

JO - Reviews in Endocrine & Metabolic Disorders

JF - Reviews in Endocrine & Metabolic Disorders

IS - 3

ER -